Skip to main content
SpringerLink
Log in

Molecular docking and 3D-QSAR study on 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert domain receptor (KDR) inhibitors

  • Original Paper
  • Published:
Journal of Molecular Modeling Aims and scope Submit manuscript

Abstract

Vascular endothselial growth factor (VEGF) and its receptor tyrosine kinase VEGFR-2 or kinase insert domain receptor (KDR) have been identified as new promising targets for the design of novel anticancer agents. It is reported that 4-(1H-indazol-4-yl)phenylamino and aminopyrazolopyridine urea derivatives exhibit potent inhibitory activities toward KDR. To investigate how their chemical structures relate to the inhibitory activities and to identify the key structural elements that are required in the rational design of potential drug candidates of this class, molecular docking simulations and three-dimensional quantitative structure-activity relationship (3D-QSAR) methods were performed on 78 4-(1H-indazol-4-yl)phenylamino and aminopyrazolopyridine urea derivatives as KDR inhibitors. Surflex-dock was used to determine the probable binding conformations of all the compounds at the active site of KDR. As a result, multiple hydrophobic and hydrogen-bonding interactions were found to be two predominant factors that may be used to modulate the inhibitory activities. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) 3D-QSAR models were developed based on the docking conformations. The CoMFA model produced statistically significant results with the cross-validated correlation coefficient q2 of 0.504 and the non-cross-validated correlation coefficient r2 of 0.913. The best CoMSIA model was obtained from the combination of steric, electrostatic and hydrophobic fields. Its q2 and r2 being 0.595 and 0.947, respectively, indicated that it had higher predictive ability than the CoMFA model. The predictive abilities of the two models were further validated by 14 test compounds, giving the predicted correction coefficients r 2pred of 0.727 for CoMFA and 0.624 for CoMSIA, respectively. In addition, the CoMFA and CoMSIA models were used to guide the design of a series of new inhibitors of this class with predicted excellent activities. Thus, these models may be used as an efficient tool to predict the inhibitory activities and to guide the future rational design of 4-(1H-indazol-4-yl)phenylamino and aminopyrazolopyridine urea derivatives-based novel KDR inhibitors with potent activities.

Molecular docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) methods were applied to a set of 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives-based KDR inhibitors

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671–674

    Article  CAS  Google Scholar 

  2. Ribatti D, Vacca A, Nico B, Roncali L, Dammacco F (2001) Postnatal vasculogenesis. Mech Dev 100:157–163

    Article  CAS  Google Scholar 

  3. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    Article  CAS  Google Scholar 

  4. Hanahan D, Folkmann J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364

    Article  CAS  Google Scholar 

  5. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327–336

    Article  CAS  Google Scholar 

  6. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027

    Article  CAS  Google Scholar 

  7. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611

    Article  CAS  Google Scholar 

  8. Baka S, Clamp AR, Jayson GC (2006) A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10:867–876

    Article  CAS  Google Scholar 

  9. Sepp-Lorenzino L, Thomas KA (2002) Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development. Expert Opin Invest Drugs 11:1447–1465

    Article  CAS  Google Scholar 

  10. Klebl BM, Müller G (2005) Second-generation kinase inhibitors. Expert Opin Ther Targets 9:975–993

    Article  CAS  Google Scholar 

  11. Supuran CT, Scozzafava A (2004) Protein tyrosine kinase inhibitors as anticancer agents. Expert Opin Ther Pat 14:35–53

    Article  CAS  Google Scholar 

  12. Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal 19:2003–2012

    Article  CAS  Google Scholar 

  13. Sakamoto KM (2004) SU-11248 (SUGEN). Curr Opin Invest Drugs 5:1329–1339

    CAS  Google Scholar 

  14. Ahman T, Eisen T (2004) Kinase inhibition with BAY43-9006 in renal cell carcinoma. Clin Cancer Res 10:6388s–6392s

    Article  Google Scholar 

  15. Dai YJ, Hartandi K, Ji ZQ, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Harris CM, Hickman D, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Martin RL, Olson AM, Osterling DJ, Pease LJ, Soni NB, Stewart KD, Stoll VS, Tapang P, Reuter DR, Davidsen SK, Michaelides MR (2007) Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N’- (2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 50:1584–1597

    Article  CAS  Google Scholar 

  16. Dai YJ, Hartandi K, Soni NB, Pease LJ, Reuter DR, Olson AM, Osterling DJ, Doktor SZ, Albert DH, Bouska JJ, Glaser KB, Marcotte PA, Stewart KD, Davidsen SK, Michaelides MR (2008) Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorg Med Chem Lett 18:386–390

    Article  CAS  Google Scholar 

  17. Cramer RD 3rd, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967

    Article  CAS  Google Scholar 

  18. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130–4146

    Article  CAS  Google Scholar 

  19. SYBYL 7.3 is available from Tripos Associates Inc, 1699 S Hanley Rd, St Louis, MO 631444, USA

  20. Jain AN (2003) Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 46:499–511

    Article  CAS  Google Scholar 

  21. Jain AN (2007) Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 21:281–306

    Article  CAS  Google Scholar 

  22. Pan J, Liu GY, Cheng J, Chen XJ, Ju XL (2010) CoMFA and molecular docking studies of benzoxazoles and benzothiazoles as CYP450 1A1 inhibitors. Eur J Med Chem 45:967–972

    Article  CAS  Google Scholar 

  23. Sun JY, Cai SX, Yan N, Mei H (2010) Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis. Eur J Med Chem 45:1008–1014

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China

    Xiaoyun Wu, Shuguang Wu & Wen-Hua Chen

Authors
  1. Xiaoyun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuguang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wen-Hua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiaoyun Wu or Wen-Hua Chen.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Table S1

CoMSIA models built from the combination of different fields (DOC 49 kb)

ESM 1

(TXT 406 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, X., Wu, S. & Chen, WH. Molecular docking and 3D-QSAR study on 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert domain receptor (KDR) inhibitors. J Mol Model 18, 1207–1218 (2012). https://doi.org/10.1007/s00894-011-1146-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00894-011-1146-9

Keywords

Search

Navigation